Nature:自体免疫药物反应中的HLA目标

2012-07-03 中国科学报 田天

基于免疫的药物反应,如“阿巴卡韦超敏反应综合征”(AHS)和“卡马西平”-诱导的“Steven Johnson综合征”(SJS),已被与特定的“人白细胞抗原”(HLA)等位基因联系起来。 刊登在Nature上的文章中,作者介绍了一个机制,这些小分子药物通过该机制影响抗原呈现,进而影响T-细胞反应。通过以非共价方式与HLA-B*57:01的“抗原结合缝”相结合,“阿巴卡韦”诱导这个点的形状和化学性

基于免疫的药物反应,如“阿巴卡韦超敏反应综合征”(AHS)和“卡马西平”-诱导的“Steven Johnson综合征”(SJS),已被与特定的“人白细胞抗原”(HLA)等位基因联系起来。

刊登在Nature上的文章中,作者介绍了一个机制,这些小分子药物通过该机制影响抗原呈现,进而影响T-细胞反应。通过以非共价方式与HLA-B*57:01的“抗原结合缝”相结合,“阿巴卡韦”诱导这个点的形状和化学性质发生变化,因而改变内生肽对HLA的亲和性。

最终,这将导致表现为AHS的系统性反应。研究人员发现,“卡马西平”也能与异形HLA-B*15:02结合、诱导一个类似的反应,这说明该机制具有普遍性。

 

doi:10.1038/nature11147
PMC:
PMID:

Immune self-reactivity triggered by drug-modified HLA-peptide repertoire

Patricia T. Illing, Julian P. Vivian, Nadine L. Dudek, Lyudmila Kostenko, Zhenjun Chen, Mandvi Bharadwaj, John J. Miles, Lars Kjer-Nielsen, Stephanie Gras, Nicholas A. Williamson, Scott R. Burrows, Anthony W. Purcell, Jamie Rossjohn & James McCluskey

Human leukocyte antigens (HLAs) are highly polymorphic proteins that initiate immunity by presenting pathogen-derived peptides to T cells1. HLA polymorphisms mostly map to the antigen-binding cleft, thereby diversifying the repertoire of self-derived and pathogen-derived peptide antigens selected by different HLA allotypes2. A growing number of immunologically based drug reactions, including abacavir…

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1952878, encodeId=e3c219528e8dc, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Sep 11 01:08:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879294, encodeId=707118e92945e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 20 15:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944054, encodeId=46a719440548e, content=<a href='/topic/show?id=2af32915564' target=_blank style='color:#2F92EE;'>#免疫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29155, encryptionId=2af32915564, topicName=免疫药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sun Apr 14 20:08:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502019, encodeId=0f6f150201999, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1952878, encodeId=e3c219528e8dc, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Sep 11 01:08:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879294, encodeId=707118e92945e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 20 15:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944054, encodeId=46a719440548e, content=<a href='/topic/show?id=2af32915564' target=_blank style='color:#2F92EE;'>#免疫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29155, encryptionId=2af32915564, topicName=免疫药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sun Apr 14 20:08:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502019, encodeId=0f6f150201999, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
    2013-03-20 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1952878, encodeId=e3c219528e8dc, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Sep 11 01:08:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879294, encodeId=707118e92945e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 20 15:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944054, encodeId=46a719440548e, content=<a href='/topic/show?id=2af32915564' target=_blank style='color:#2F92EE;'>#免疫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29155, encryptionId=2af32915564, topicName=免疫药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sun Apr 14 20:08:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502019, encodeId=0f6f150201999, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1952878, encodeId=e3c219528e8dc, content=<a href='/topic/show?id=49ff8e70301' target=_blank style='color:#2F92EE;'>#药物反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87703, encryptionId=49ff8e70301, topicName=药物反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da20314, createdName=lfcmxl, createdTime=Tue Sep 11 01:08:00 CST 2012, time=2012-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879294, encodeId=707118e92945e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 20 15:08:00 CST 2013, time=2013-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944054, encodeId=46a719440548e, content=<a href='/topic/show?id=2af32915564' target=_blank style='color:#2F92EE;'>#免疫药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29155, encryptionId=2af32915564, topicName=免疫药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d1e370, createdName=yibei, createdTime=Sun Apr 14 20:08:00 CST 2013, time=2013-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1502019, encodeId=0f6f150201999, content=<a href='/topic/show?id=14a6894190' target=_blank style='color:#2F92EE;'>#HLA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8941, encryptionId=14a6894190, topicName=HLA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e72c9501412, createdName=marongnuan, createdTime=Thu Jul 05 07:08:00 CST 2012, time=2012-07-05, status=1, ipAttribution=)]
    2012-07-05 marongnuan

相关资讯

Nature:心肌梗塞加重动脉粥样硬化进展

6月27日,Nature杂志在线报道了心肌梗塞加重动脉粥样硬化机制的最新进展。 在动脉粥样硬化的进展过程中,髓样细胞使富含脂质的动脉壁斑块不稳定,并导致其破裂,从而引发心肌梗塞和中风。由于尚不清楚的原因,急性冠脉综合征的幸存者具有高度复发风险。 本研究表明,缺血性损伤的系统性反应可加重慢性动脉粥样硬化。载脂蛋白E-/ -(Apoe-/-)小鼠心肌梗死或中风后,发生了更严重的,形态较大的动脉粥样

Nature:科学家揭示热量限制和小肠功能之间的联系

减少热量摄取同时维持充足营养可延长多种不同生物的寿命,这可能是通过保持干细胞和先祖细胞的功能来进行的。刊登在Nature上的一篇报道揭示了热量限制和小肠功能之前的联系 David Sabatini及其同事发现,在小鼠的小肠中,热量限制导致具有增强的再生能力的小肠干细胞(ISC)数量增加。这种效应可通过Paneth细胞(ISC生存环境中的重要成分)中的mTOR信号作用的调制来介导。热量限制导致Pa

Nature:TLR9在心肌炎发病中起关键作用

近日,日本研究人员在新一期Nature杂志上报告说,他们发现了作为心力衰竭原因之一的心肌炎的发病机制。这一发现有助于开发治疗心力衰竭的新方法。 大阪大学等机构研究人员报告说,他们通过动物实验发现,由于高血压等原因使心肌细胞内的线粒体受损后,导致无用的线粒体DNA蓄积,这会引发“过度”的免疫反应,而这是炎症发生的导火索。研究人员首先培育出无法分解心肌细胞内线粒体DNA的小鼠,然后利用这种小鼠进行了

Nature:抗-EGFR疗法中的获得性抗药性

近日,Nature上两篇论文表明,K-Ras突变在临床抗药性/复发出现之前可以在患者血清中检测到。使用以“表皮生长因子受体”(EGFR)为目标的抗体,已成为治疗结肠直肠癌的一种成熟方法,但它们不能用于KRAS致癌基因上携带突变的患者。抗药性还会在最初有疗效的患者身上出现。 这两篇论文提出的明确证据表明,KRAS基因的突变是造成很多患者对“抗-EGFR抗体”产生获得性抗药性的原因。Misale等人

Nature:研究揭示三阴乳腺癌难治的根源

一个由加拿大、英国、美国的59名研究人员组成的国际研究小组最新发表的研究报告显示,他们从分子层面的研究发现,不同三阴乳腺癌肿瘤的基因组其实存在很大差异,这也是常用药物对这类癌症疗效不大的重要因素,未来可能需要调整相关的治疗手法。相关论文4月4日在线发表于《Nature》. 研究人员利用电脑技术分析了100个三阴乳腺癌肿瘤的基因组,结果发现它们中没有任何两个相似,更不用说完全一样。研究人员说,鉴于

Nature:两项研究证实上皮组织细胞数量控制或与癌症有关

如果一个上皮细胞层要保持其结构,并且为机体提供一个保护壁垒,它就需要在正在分裂的细胞数量与正在死亡的细胞数量之间维持平衡。虽然补偿细胞的分裂可能被死亡细胞所触发,但是,细胞死亡如何减轻细胞增殖所带来的“拥挤”,目前尚不明了。 4月26日出版的《自然》杂志同时发表了两篇有关上皮组织细胞数量控制的文章,指出维持上皮组织细胞平衡的机理可能与癌症有关。 英国伦敦大学学院分子细胞学实验室的Buzz Ba